[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"nav-header":3,"nav-footer":48,"news-list":63,"footer-settings":766},{"id":4,"headerLinks":5,"footerColumns":45,"updatedAt":46,"createdAt":46,"globalType":47},1,[6,35,40],{"id":7,"label":8,"url":9,"children":10},"6a2aae5bc05f95ffe884f04a","Knowledge","",[11,15,19,23,27,31],{"id":12,"label":13,"url":14},"6a2aae5bc05f95ffe884f044","Knowledge Hub","\u002Fknowledge-hub",{"id":16,"label":17,"url":18},"6a2aae5bc05f95ffe884f045","Good Simulation Practice","\u002Fknowledge-hub\u002Fgood-simulation-practice",{"id":20,"label":21,"url":22},"6a2aae5bc05f95ffe884f046","Good AI Practice","\u002Fknowledge-hub\u002Fgood-ai-practice",{"id":24,"label":25,"url":26},"6a2aae5bc05f95ffe884f047","Scientific Publications","\u002Flibrary",{"id":28,"label":29,"url":30},"6a2aae5bc05f95ffe884f048","Scientific Posters","\u002Fposters",{"id":32,"label":33,"url":34},"6a2aae5bc05f95ffe884f049","News","\u002Fnews",{"id":36,"label":37,"url":38,"children":39},"6a2aae5bc05f95ffe884f04b","Innovation","\u002Fresearch-projects",[],{"id":41,"label":42,"url":43,"children":44},"6a2adaf780e94f5b62b46d1f","About","\u002Fabout",[],[],"2026-06-11T11:10:54.397Z","navigation",{"id":4,"headerLinks":49,"footerColumns":62,"updatedAt":46,"createdAt":46,"globalType":47},[50,58,60],{"id":7,"label":8,"url":9,"children":51},[52,53,54,55,56,57],{"id":12,"label":13,"url":14},{"id":16,"label":17,"url":18},{"id":20,"label":21,"url":22},{"id":24,"label":25,"url":26},{"id":28,"label":29,"url":30},{"id":32,"label":33,"url":34},{"id":36,"label":37,"url":38,"children":59},[],{"id":41,"label":42,"url":43,"children":61},[],[],{"docs":64,"hasNextPage":664,"hasPrevPage":664,"limit":765,"nextPage":71,"page":4,"pagingCounter":4,"prevPage":71,"totalDocs":649,"totalPages":4},[65,77,87,285,296,307,317,327,337,347,357,415,425,435,445,455,465,474,483,492,502,511,521,531,541,550,559,568,577,586,594,603,612,621,631,639,648],{"id":4,"title":66,"slug":67,"date":68,"tag":69,"excerpt":70,"coverImage":71,"source":72,"externalUrl":73,"body":71,"legacyUrl":71,"updatedAt":74,"createdAt":75,"_status":76},"InSilicoTrials Joins Microsoft for Startups Pegasus Program to Accelerate Digital Transformation in Healthcare","insilicotrials-joins-microsoft-for-startups-pegasus-program-to-accelerate-digita","2025-06-11T00:00:00.000Z","Partnership","InSilicoTrials joins Microsoft for Startups Pegasus Program, accessing enterprise-grade cloud tools and go-to-market support to accelerate its AI-driven drug development platform.",null,"Press release · Microsoft for Startups","http:\u002F\u002Flocalhost:3001\u002Fapi\u002Fmedia\u002Ffile\u002FPress_Release_Microsoft.pdf","2026-05-25T08:48:07.582Z","2026-05-25T07:59:57.954Z","published",{"id":78,"title":79,"slug":80,"date":81,"tag":69,"excerpt":82,"coverImage":71,"source":83,"externalUrl":84,"body":71,"legacyUrl":71,"updatedAt":85,"createdAt":86,"_status":76},2,"InSilicoTrials Expands Platform with Advanced Predictive Models from COSBI","insilicotrials-expands-platform-with-advanced-predictive-models-from-cosbi","2025-05-12T00:00:00.000Z","InSilicoTrials integrates COSBI's mechanistic modelling capabilities into its platform, adding new predictive models that enhance regulatory-grade simulation for drug development.","Press release · COSBI","http:\u002F\u002Flocalhost:3001\u002Fapi\u002Fmedia\u002Ffile\u002FPress_Release_COSBI.pdf","2026-05-25T08:48:07.539Z","2026-05-25T07:59:57.996Z",{"id":88,"title":89,"slug":90,"date":91,"tag":92,"excerpt":93,"coverImage":71,"source":94,"externalUrl":95,"body":96,"legacyUrl":71,"updatedAt":283,"createdAt":284,"_status":76},3,"FDA's Strategic Roadmap to Phase Out Animal Testing: How Computational Models Are Revolutionizing Drug Development","fda-announces-plan-to-phase-out-animal-testing-requirement-for-monoclonal-antibo","2025-05-06T00:00:00.000Z","Regulatory","The FDA's strategic shift signals broader regulatory acceptance of computational alternatives — over 90% of drugs that succeed in animals fail in humans.","News · FDA","https:\u002F\u002Finsilicotrials.com\u002Ffdas-strategic-roadmap-to-phase-out-animal-testing-how-computational-models-are-revolutionizing-drug-development\u002F",{"root":97},{"type":98,"format":9,"indent":99,"version":4,"children":100},"root",0,[101,107,122,128,132,136,140,144,148,152,156,160,164,182,186,200,204,218,222,226,230,234,238,248,256,265,274],{"type":102,"format":9,"indent":99,"version":4,"children":103},"paragraph",[104],{"text":105,"type":106,"format":4,"version":4},"The Paradigm Shift in Preclinical Testing","text",{"type":102,"format":9,"indent":99,"version":4,"children":108},[109,111,120],{"text":110,"type":106,"format":99,"version":4}," The ",{"url":112,"type":113,"fields":114,"version":4,"children":117},"https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpress-announcements\u002Ffda-announces-plan-phase-out-animal-testing-requirement-monoclonal-antibodies-and-other-drugs","link",{"url":112,"newTab":115,"linkType":116},true,"custom",[118],{"text":119,"type":106,"format":99,"version":4},"FDA has announced a strategic shift",{"text":121,"type":106,"format":99,"version":4}," away from animal testing, citing that over 90% of drugs successful in animals fail FDA approval due to human safety and efficacy issues—especially in cancer, Alzheimer's, and inflammatory diseases¹˒². Their new roadmap focuses on New Approach Methodologies (NAMs): in vitro human-based systems, in silico computational modeling, and innovative platforms for evaluating immunogenicity, toxicity, and pharmacodynamics in humans².",{"type":102,"format":9,"indent":99,"version":4,"children":123},[124,126],{"text":125,"type":106,"format":4,"version":4},"Preclinical paradox:",{"text":127,"type":106,"format":99,"version":4}," Did you know? Aspirin might never have reached patients if it had to pass modern animal testing, while compounds \"safe\" in animals have proven fatal in humans³ .",{"type":102,"format":9,"indent":99,"version":4,"children":129},[130],{"text":131,"type":106,"format":99,"version":4},"At InSilicoTrials, our computational platforms directly support this transition by providing pharmaceutical companies with human-relevant alternatives that improve predictive accuracy and align with the FDA's stepwise approach to modernizing preclinical testing.",{"type":102,"format":9,"indent":99,"version":4,"children":133},[134],{"text":135,"type":106,"format":4,"version":4},"Why Start with Monoclonal Antibodies?",{"type":102,"format":9,"indent":99,"version":4,"children":137},[138],{"text":139,"type":106,"format":99,"version":4}," The strategic rollout: The agency's carefully sequenced approach begins with mAbs, where animal tests have most dramatically failed human prediction, before expanding to other biologics and eventually all drugs. This science-driven strategy targets the $187 billion mAb market first, where catastrophic failures like TGN1412 have demonstrated that passing animal studies provides false security. By establishing success with mAbs, FDA creates momentum for broader implementation while protecting the most patients in the shortest timeframe⁴˒⁵.",{"type":102,"format":9,"indent":99,"version":4,"children":141},[142],{"text":143,"type":106,"format":99,"version":4},"While mAbs serve as the FDA's starting point, could this be the first domino in a larger shift across the biologics landscape? This broader category includes recombinant proteins, gene therapies, cell-based products, and vaccines, representing a rapidly growing sector of pharmaceutical development. Biologics present unique challenges for traditional animal testing due to their complex structures and species-specific interactions with immune systems.",{"type":102,"format":9,"indent":99,"version":4,"children":145},[146],{"text":147,"type":106,"format":4,"version":4},"How InSilicoTrials Aligns with FDA's New Vision",{"type":102,"format":9,"indent":99,"version":4,"children":149},[150],{"text":151,"type":106,"format":99,"version":4}," InSilicoTrials delivers regulatory-compliant computational solutions that transform drug development in the post-animal testing era.",{"type":102,"format":9,"indent":99,"version":4,"children":153},[154],{"text":155,"type":106,"format":99,"version":4},"The FDA is actively promoting AI and simulation to predict drug behavior in the human body. These approaches can forecast distribution, metabolism, target engagement, and side effects while catching safety issues earlier. By accepting real-world human data from other countries and offering streamlined reviews for companies using robust in silico methods, the FDA is creating powerful incentives for computational innovation.",{"type":102,"format":9,"indent":99,"version":4,"children":157},[158],{"text":159,"type":106,"format":4,"version":4},"Our Advanced Solutions Portfolio",{"type":102,"format":9,"indent":99,"version":4,"children":161},[162],{"text":163,"type":106,"format":4,"version":4},"Comprehensive Drug Modeling:",{"tag":165,"type":166,"start":4,"indent":99,"version":4,"children":167,"listType":181},"ul","list",[168,173,177],{"type":169,"value":4,"indent":99,"checked":71,"version":4,"children":170},"listitem",[171],{"text":172,"type":106,"format":99,"version":4},"PBPK & QSP Models: Simulate biologic therapies and patient responses across virtual populations",{"type":169,"value":78,"indent":99,"checked":71,"version":4,"children":174},[175],{"text":176,"type":106,"format":99,"version":4},"PK & ADME: Generate predictions based on molecular structures",{"type":169,"value":88,"indent":99,"checked":71,"version":4,"children":178},[179],{"text":180,"type":106,"format":99,"version":4},"PhysChem + Blood Brain Barrier: Predict BBB penetration and key molecular descriptors","bullet",{"type":102,"format":9,"indent":99,"version":4,"children":183},[184],{"text":185,"type":106,"format":4,"version":4},"AI-Driven Safety Assessment:",{"tag":165,"type":166,"start":4,"indent":99,"version":4,"children":187,"listType":181},[188,192,196],{"type":169,"value":4,"indent":99,"checked":71,"version":4,"children":189},[190],{"text":191,"type":106,"format":99,"version":4},"Mutagenicity: Non-animal, ICH-compliant QSAR models for predicting genotoxicity",{"type":169,"value":78,"indent":99,"checked":71,"version":4,"children":193},[194],{"text":195,"type":106,"format":99,"version":4},"Chemotoxicity: Predict immunotherapy effects using digital patient populations",{"type":169,"value":88,"indent":99,"checked":71,"version":4,"children":197},[198],{"text":199,"type":106,"format":99,"version":4},"Immunogenicity Risk Screen: Mimic CD4+ T-cell assays to assess protein sequence risks",{"type":102,"format":9,"indent":99,"version":4,"children":201},[202],{"text":203,"type":106,"format":4,"version":4},"Target Interaction Analysis:",{"tag":165,"type":166,"start":4,"indent":99,"version":4,"children":205,"listType":181},[206,210,214],{"type":169,"value":4,"indent":99,"checked":71,"version":4,"children":207},[208],{"text":209,"type":106,"format":99,"version":4},"Target Affinity Prediction: AI-powered assessment across >1M compound records",{"type":169,"value":78,"indent":99,"checked":71,"version":4,"children":211},[212],{"text":213,"type":106,"format":99,"version":4},"Molecular Docking: Simulate ligand-target interactions to assess binding affinity",{"type":169,"value":88,"indent":99,"checked":71,"version":4,"children":215},[216],{"text":217,"type":106,"format":99,"version":4},"Epitope Identification: Deep learning models for protein-protein interactions",{"type":102,"format":9,"indent":99,"version":4,"children":219},[220],{"text":221,"type":106,"format":99,"version":4}," Furthermore, by partnering with InSilicoTrials, pharmaceutical companies can immediately access FDA-aligned computational solutions to accelerate development timelines, reduce costs, and strategically position them for the FDA's new regulatory incentives, all while delivering safer, more effective therapies to patients with unprecedented speed.",{"type":102,"format":9,"indent":99,"version":4,"children":223},[224],{"text":225,"type":106,"format":4,"version":4},"Next Steps and Key Takeaways",{"type":102,"format":9,"indent":99,"version":4,"children":227},[228],{"text":229,"type":106,"format":99,"version":4}," The FDA's strategic roadmap marks a pivotal shift away from animal testing toward scientifically validated NAMs. This transition promises multiple benefits: patients will receive safer therapies faster, unnecessary animal testing will be eliminated, and drug development will align with 21st-century technology. ",{"type":102,"format":9,"indent":99,"version":4,"children":231},[232],{"text":233,"type":106,"format":99,"version":4},"The future of drug development is computational, ethical, and human-relevant, and the time to embrace this transformation is now.",{"type":102,"format":9,"indent":99,"version":4,"children":235},[236],{"text":237,"type":106,"format":4,"version":4},"References",{"type":102,"format":9,"indent":99,"version":4,"children":239},[240,242],{"text":241,"type":106,"format":99,"version":4},"¹ NIH Advisory Committee to the Director, \"NAMs Working Group Report,\" December 2023. ",{"url":243,"type":113,"fields":244,"version":4,"children":245},"https:\u002F\u002Fwww.acd.od.nih.gov\u002Fdocuments\u002Fpresentations\u002F12142023_NAMs_Working_Group_Report.pdf",{"url":243,"newTab":115,"linkType":116},[246],{"text":247,"type":106,"format":99,"version":4},"[Link]",{"type":102,"format":9,"indent":99,"version":4,"children":249},[250,252],{"text":251,"type":106,"format":99,"version":4},"² FDA, \"FDA Announces Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs,\" April 2024. ",{"url":112,"type":113,"fields":253,"version":4,"children":254},{"url":112,"newTab":115,"linkType":116},[255],{"text":247,"type":106,"format":99,"version":4},{"type":102,"format":9,"indent":99,"version":4,"children":257},[258,260],{"text":259,"type":106,"format":99,"version":4},"³ Bailey J. \"Does the stress of laboratory life and experimentation on animals adversely affect research data?\" Altern Lab Anim. 2018;46(5):291-305. ",{"url":261,"type":113,"fields":262,"version":4,"children":263},"https:\u002F\u002Fpubmed.ncbi.nlm.nih.gov\u002F30488713\u002F",{"url":261,"newTab":115,"linkType":116},[264],{"text":247,"type":106,"format":99,"version":4},{"type":102,"format":9,"indent":99,"version":4,"children":266},[267,269],{"text":268,"type":106,"format":99,"version":4},"⁴ Labmate Online, \"Market Report: Therapeutic Monoclonal Antibodies in Europe\" ",{"url":270,"type":113,"fields":271,"version":4,"children":272},"https:\u002F\u002Fwww.labmate-online.com\u002Fnews\u002Fnews-and-views\u002F5\u002Ffrost-sullivan\u002Fmarket-report-therapeutic-monoclonal-antibodies-in-europe\u002F22346",{"url":270,"newTab":115,"linkType":116},[273],{"text":247,"type":106,"format":99,"version":4},{"type":102,"format":9,"indent":99,"version":4,"children":275},[276,278],{"text":277,"type":106,"format":99,"version":4},"⁵ NC3Rs, \"Reducing animal use in monoclonal antibody development\" ",{"url":279,"type":113,"fields":280,"version":4,"children":281},"https:\u002F\u002Fnc3rs.org.uk\u002Four-portfolio\u002Freducing-animal-use-monoclonal-antibody-development",{"url":279,"newTab":115,"linkType":116},[282],{"text":247,"type":106,"format":99,"version":4},"2026-05-25T09:02:47.748Z","2026-05-25T07:59:58.025Z",{"id":286,"title":287,"slug":288,"date":289,"tag":290,"excerpt":291,"coverImage":71,"source":292,"externalUrl":293,"body":71,"legacyUrl":71,"updatedAt":294,"createdAt":295,"_status":76},4,"New Paper: Synthetic Data in Healthcare and Drug Development — Definitions, Regulatory Frameworks, Issues","new-paper-synthetic-data-in-healthcare-and-drug-development-definitions-regulato","2025-04-07T00:00:00.000Z","Research","Peer-reviewed paper in CPT: Pharmacometrics & Systems Pharmacology defining synthetic data, outlining regulatory frameworks, and mapping open challenges in healthcare applications.","Research · CPT: PSP","https:\u002F\u002Fascpt.onlinelibrary.wiley.com\u002Fdoi\u002F10.1002\u002Fpsp4.70021","2026-05-25T08:44:58.451Z","2026-05-25T07:59:58.070Z",{"id":297,"title":298,"slug":299,"date":300,"tag":301,"excerpt":302,"coverImage":71,"source":303,"externalUrl":304,"body":71,"legacyUrl":71,"updatedAt":305,"createdAt":306,"_status":76},5,"InSilicoTrials is Among Italy's Top Innovators","insilicotrials-is-among-italy-s-top-innovators","2025-02-17T00:00:00.000Z","Awards","InSilicoTrials appears in Corriere della Sera's annual ranking of Italy's top 130 innovative companies, recognising its contribution to computational drug development.","News · Corriere della Sera","https:\u002F\u002Fwww.corriere.it\u002Feconomia\u002Fleader-dell-innovazione\u002F?top130italiane","2026-05-25T08:44:58.475Z","2026-05-25T07:59:58.106Z",{"id":308,"title":309,"slug":310,"date":311,"tag":301,"excerpt":312,"coverImage":71,"source":313,"externalUrl":314,"body":71,"legacyUrl":71,"updatedAt":315,"createdAt":316,"_status":76},6,"InSilicoTrials Recognized in the HSBC 2024 Annual Venture Healthcare Report","insilicotrials-recognized-in-the-hsbc-2024-annual-venture-healthcare-report","2025-01-28T00:00:00.000Z","InSilicoTrials is featured in HSBC's 2024 Venture Healthcare Report, which highlights the most promising healthcare startups globally across diagnostics, therapeutics, and digital health.","HSBC Venture Healthcare","https:\u002F\u002Finsilicotrials.com\u002Finsilicotrials_highlighted_in_hsbc_venture_healthcare_report\u002F","2026-05-25T08:44:58.498Z","2026-05-25T07:59:58.136Z",{"id":318,"title":319,"slug":320,"date":321,"tag":69,"excerpt":322,"coverImage":71,"source":323,"externalUrl":324,"body":71,"legacyUrl":71,"updatedAt":325,"createdAt":326,"_status":76},7,"AVL Partners With InSilicoTrials To Extend Simulation Offering For Healthcare Industry","avl-partners-with-insilicotrials-to-extend-simulation-offering-for-healthcare-in","2024-09-25T00:00:00.000Z","AVL and InSilicoTrials partner to deliver integrated simulation workflows across automotive and healthcare engineering — enabling multi-physics in silico testing at scale.","Press release · AVL","https:\u002F\u002Fwww.avl.com\u002Fen\u002Fnews\u002Favl-partners-insilicotrials-extend-simulation-offering-healthcare-industry","2026-05-25T08:44:58.519Z","2026-05-25T07:59:58.168Z",{"id":328,"title":329,"slug":330,"date":331,"tag":92,"excerpt":332,"coverImage":71,"source":333,"externalUrl":334,"body":71,"legacyUrl":71,"updatedAt":335,"createdAt":336,"_status":76},8,"Advancing Drug Development: FDA's Take on In Silico Trials","advancing-drug-development-fda-s-take-on-in-silico-trials","2024-08-12T00:00:00.000Z","Clinical Trial Vanguard coverage of FDA's perspective on in silico trials — including the agency's support for computational alternatives to accelerate drug development.","News · Clinical Trial Vanguard","https:\u002F\u002Fwww.clinicaltrialvanguard.com\u002Fconference-coverage\u002Fadvancing-drug-development-fdas-take-on-in-silico-trials\u002F","2026-05-25T08:44:58.543Z","2026-05-25T07:59:58.210Z",{"id":338,"title":339,"slug":340,"date":341,"tag":301,"excerpt":342,"coverImage":71,"source":343,"externalUrl":344,"body":71,"legacyUrl":71,"updatedAt":345,"createdAt":346,"_status":76},9,"InSilicoTrials Wins AI Startup of the Year Award at Startup Grind Global 2024","insilicotrials-wins-ai-startup-of-the-year-award-at-startup-grind-global-2024","2024-05-31T00:00:00.000Z","InSilicoTrials receives the AI Startup of the Year award at Startup Grind Global 2024, recognising its platform's impact on accelerating pharmaceutical research through simulation.","Press release · Startup Grind","http:\u002F\u002Flocalhost:3001\u002Fapi\u002Fmedia\u002Ffile\u002FPress_Release_StartupGrind.pdf","2026-05-25T08:48:07.486Z","2026-05-25T07:59:58.272Z",{"id":348,"title":349,"slug":350,"date":351,"tag":92,"excerpt":352,"coverImage":71,"source":353,"externalUrl":354,"body":71,"legacyUrl":71,"updatedAt":355,"createdAt":356,"_status":76},10,"FDA Purchases XPS License — Developed by RCPE and Distributed by InSilicoTrials — as In-House Simulation Tool","fda-purchases-xps-license-developed-by-rcpe-and-distributed-by-insilicotrials-as","2024-04-04T00:00:00.000Z","The FDA has acquired an XPS simulation license for internal use, directly validating InSilicoTrials' regulatory-grade computational tools for pharmaceutical manufacturing.","Press release · RCPE \u002F InSilicoTrials","http:\u002F\u002Flocalhost:3001\u002Fapi\u002Fmedia\u002Ffile\u002FPress_Release_collab_RCPE_april_24.pdf","2026-05-25T08:48:07.423Z","2026-05-25T07:59:58.331Z",{"id":358,"title":359,"slug":360,"date":361,"tag":362,"excerpt":363,"coverImage":71,"source":364,"externalUrl":365,"body":366,"legacyUrl":71,"updatedAt":413,"createdAt":414,"_status":76},11,"Telomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore Conference","telomir-pharmaceuticals-presents-promising-pre-clinical-data-for-its-lead-develo","2024-03-07T00:00:00.000Z","Press release","Telomir Pharmaceuticals presents pre-clinical simulation data generated using InSilicoTrials' platform at an international conference in Singapore, demonstrating in silico efficacy of its lead candidate.","Press release · GlobeNewsWire","https:\u002F\u002Fwww.globenewswire.com\u002Fnews-release\u002F2024\u002F03\u002F07\u002F2842251\u002F0\u002Fen\u002FTelomir-Pharmaceuticals-Presents-Promising-Pre-Clinical-Data-For-Its-Lead-Development-Product-at-Singapore-Conference.html",{"root":367},{"type":98,"format":9,"indent":99,"version":4,"children":368},[369,375,385,397,401,405,409],{"tag":370,"type":371,"format":9,"indent":99,"version":4,"children":372},"h5","heading",[373],{"text":374,"type":106,"format":99,"version":4},"InSilicoTrials collaborates with Telomir Pharmaceuticals, applying cutting-edge AI and simulation technologies to optimize the development of Telomir-1, a promising agent in the battle against age-related conditions, by improving its safety profile and reducing development costs.",{"type":102,"format":9,"indent":99,"version":4,"children":376},[377,379,381,383],{"text":378,"type":106,"format":99,"version":4},"BALTIMORE, March 07, 2024 (GLOBE NEWSWIRE) -- ",{"text":380,"type":106,"format":4,"version":4},"Telomir Pharmaceuticals, Inc.",{"text":382,"type":106,"format":4,"version":4},"(Nasdaq:TELO)",{"text":384,"type":106,"format":99,"version":4}," (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to potentially reverse age-related conditions, today announced that Telomir, alongside its partner Frontage Laboratories, presented a scientific poster at the National University Health System of Singapore (NUHS) Centre for Healthy Longevity Conference 2024 with data showing the effect of Telomir-1 on telomere length in three human cell lines: MRC-5 fetal lung fibroblasts, human umbilical endothelial cells (HUVEC), and mesenchymal stem cells (MSC). The data presented was garnered from pre-clinical studies that Telomir previously disclosed it was undertaking.",{"type":102,"format":9,"indent":99,"version":4,"children":386},[387,389,391,393,395],{"text":388,"type":106,"format":99,"version":4},"Danielle R. Baker, Ph.D., of Frontage Laboratories, presented the poster, titled “Telomir-1 Induces Telomere Extensions in Primary Human Cell Strains,” at the conference, which took place in Singapore, on February 29",{"text":390,"type":106,"format":99,"version":4},"th",{"text":392,"type":106,"format":99,"version":4}," and March 1",{"text":394,"type":106,"format":99,"version":4},"st",{"text":396,"type":106,"format":99,"version":4},". The data presented further demonstrated how Telomir-1 increases telomere length and its potential to successfully affect age-related inflammatory conditions.",{"type":102,"format":9,"indent":99,"version":4,"children":398},[399],{"text":400,"type":106,"format":99,"version":4},"“We are honored that this poster was accepted for presentation at the NUHS Conference. Moreover, the promising data we presented at the NUHS Conference showed the advances we are making at potentially treating age-related conditions and prolonging human life,” stated Chris Chapman, MD, co-founder, chairman, chief executive officer and president of Telomir. “If Telomir-1 can safely extend telomeres in people, it could vastly alter the aging process and redefine our potential for living longer, healthier lives. We are excited at what the future holds and we look forward to presenting additional data to the longevity community in the coming months.”",{"type":102,"format":9,"indent":99,"version":4,"children":402},[403],{"text":404,"type":106,"format":99,"version":4},"Dr. Michael Roizen, special advisor to Telomir, added, “While more research is needed, these preliminary findings open up the possibility that many diseases long considered inevitable consequences of aging could become avoidable. This study further demonstrates our belief that Telomir-1 may have the effect of reversing age through telomere regeneration, enabling the production of more stem cells, essentially allowing an individual to repair oneself.”",{"type":102,"format":9,"indent":99,"version":4,"children":406},[407],{"text":408,"type":106,"format":99,"version":4},"The conference was orchestrated by the NUHS Centre for Healthy Longevity, a distinguished entity devoted to extending healthy life by delaying aging, prolonging disease-free life, and maintaining high functionality. Through rigorous research and strategic implementations, the NUHS Centre strives to unveil and promote innovative geroprotective interventions. The CHL Conference 2024 serves as a hallmark event, reflecting the NUHS Centre's steadfast commitment to fostering a collaborative environment, facilitating discourse, and propelling the field of healthy longevity forward.",{"type":102,"format":9,"indent":99,"version":4,"children":410},[411],{"text":412,"type":106,"format":99,"version":4},"As part of its ongoing work on Telomir-1, the Company collaborated with InSilicoTrials, an innovator in leveraging AI and simulations to enhance drug development, to perform advanced AI modeling on Telomir-1. Early research has confirmed the mechanism of action of Telomir-1 and suggests that it may be a potent metal inhibitor, potentially leading to a reversal of aging through telomere regeneration. The collaboration is expected to help accelerate the development of Telomir-1, improve its safety profile, and significantly reduce the research and development costs of Telomir’s drug development program.","2026-05-25T08:44:58.608Z","2026-05-25T07:59:58.402Z",{"id":416,"title":417,"slug":418,"date":419,"tag":362,"excerpt":420,"coverImage":71,"source":421,"externalUrl":422,"body":71,"legacyUrl":71,"updatedAt":423,"createdAt":424,"_status":76},12,"Launch of Ground-Breaking 'Toward Good Simulation Practice' Book to Set New Standards in Biomedical Simulation","launch-of-ground-breaking-toward-good-simulation-practice-book-to-set-new-standa","2024-03-05T00:00:00.000Z","The open-access book 'Toward Good Simulation Practice' is officially launched, establishing best-practice guidelines for computational modelling in regulatory submissions and clinical research.","Press release · InSilicoTrials","http:\u002F\u002Flocalhost:3001\u002Fapi\u002Fmedia\u002Ffile\u002FPress_Release_GSP_March24.pdf","2026-05-25T08:48:07.383Z","2026-05-25T07:59:58.430Z",{"id":426,"title":427,"slug":428,"date":429,"tag":430,"excerpt":431,"coverImage":71,"source":421,"externalUrl":432,"body":71,"legacyUrl":71,"updatedAt":433,"createdAt":434,"_status":76},13,"Dr. Daniel Röshammar Joins InSilicoTrials as Vice President of Research & Development","dr-daniel-r-shammar-joins-insilicotrials-as-vice-president-of-research-developme","2024-02-12T00:00:00.000Z","Personnel","Dr. Daniel Röshammar, a leading expert in pharmacometrics and model-informed drug development, joins InSilicoTrials as VP of R&D to strengthen its scientific and regulatory capabilities.","http:\u002F\u002Flocalhost:3001\u002Fapi\u002Fmedia\u002Ffile\u002FPress_Release_collab_Daniel.pdf","2026-05-25T08:48:07.341Z","2026-05-25T07:59:58.454Z",{"id":436,"title":437,"slug":438,"date":439,"tag":362,"excerpt":440,"coverImage":71,"source":441,"externalUrl":442,"body":71,"legacyUrl":71,"updatedAt":443,"createdAt":444,"_status":76},14,"Innovator Spotlight with Luca Emili","innovator-spotlight-with-luca-emili","2024-02-07T00:00:00.000Z","Dealflow.eu features InSilicoTrials CEO Luca Emili in its Innovator Spotlight series — discussing the future of in silico medicine, regulatory challenges, and the platform's growth roadmap.","Feature · Dealflow.eu","https:\u002F\u002Fdealflow.eu\u002Finnovator-spotlight-with-luca-emili\u002F","2026-05-25T08:44:58.690Z","2026-05-25T07:59:58.483Z",{"id":446,"title":447,"slug":448,"date":449,"tag":69,"excerpt":450,"coverImage":71,"source":451,"externalUrl":452,"body":71,"legacyUrl":71,"updatedAt":453,"createdAt":454,"_status":76},15,"MIRA Pharmaceuticals Releases Breakthrough Data from Artificial Intelligence Simulations in Collaboration with InSilicoTrials","mira-pharmaceuticals-releases-breakthrough-data-from-artificial-intelligence-sim","2023-12-04T00:00:00.000Z","MIRA Pharmaceuticals publishes breakthrough pre-clinical simulation data generated in collaboration with InSilicoTrials, supporting its lead therapeutic candidate's development pipeline.","Press release · PRNewswire","https:\u002F\u002Fwww.prnewswire.com\u002Fnews-releases\u002Fmira-pharmaceuticals-releases-breakthrough-data-from-artificial-intelligence-simulations-302004158.html","2026-05-25T08:44:58.714Z","2026-05-25T07:59:58.528Z",{"id":456,"title":457,"slug":458,"date":459,"tag":301,"excerpt":460,"coverImage":71,"source":461,"externalUrl":462,"body":71,"legacyUrl":71,"updatedAt":463,"createdAt":464,"_status":76},16,"InSilicoTrials Awarded 2023 Innovation Radar Prize Established by European Commission in AI and Smart Devices Category","insilicotrials-awarded-2023-innovation-radar-prize-established-by-european-commi","2023-11-15T00:00:00.000Z","InSilicoTrials receives the prestigious 2023 Innovation Radar Prize from the European Commission in the AI and Smart Devices category, recognising its impact within EU Horizon projects.","Press release · European Commission","http:\u002F\u002Flocalhost:3001\u002Fapi\u002Fmedia\u002Ffile\u002FPress_Release_AI_Winner.pdf","2026-05-25T08:48:07.286Z","2026-05-25T07:59:58.565Z",{"id":466,"title":467,"slug":468,"date":469,"tag":430,"excerpt":470,"coverImage":71,"source":421,"externalUrl":471,"body":71,"legacyUrl":71,"updatedAt":472,"createdAt":473,"_status":76},17,"Mark Lovern Joins InSilicoTrials as Chief Platform Officer","mark-lavern-joins-insilicotrials-as-chief-platform-officer","2023-10-17T00:00:00.000Z","Mark Lovern joins InSilicoTrials as Chief Platform Officer, bringing deep expertise in enterprise SaaS and healthcare technology to accelerate the platform's global commercial expansion.","http:\u002F\u002Flocalhost:3001\u002Fapi\u002Fmedia\u002Ffile\u002FPress_Release_Mark_.pdf","2026-05-25T08:48:07.225Z","2026-05-25T07:59:58.585Z",{"id":475,"title":476,"slug":477,"date":478,"tag":69,"excerpt":479,"coverImage":71,"source":421,"externalUrl":480,"body":71,"legacyUrl":71,"updatedAt":481,"createdAt":482,"_status":76},18,"InSilicoTrials and Axoltis Pharma Collaborate to Advance Therapeutic Solutions for Neurological Disorders","insilicotrials-and-axoltis-pharma-collaborate-to-advance-therapeutic-solutions-f","2023-07-27T00:00:00.000Z","InSilicoTrials and Axoltis Pharma join forces to apply computational modelling to neurological drug development, targeting conditions with high unmet medical need and limited therapeutic options.","http:\u002F\u002Flocalhost:3001\u002Fapi\u002Fmedia\u002Ffile\u002FPress_Release_collab_axoltisindd.pdf","2026-05-25T08:48:07.167Z","2026-05-25T07:59:58.606Z",{"id":484,"title":485,"slug":486,"date":487,"tag":69,"excerpt":488,"coverImage":71,"source":83,"externalUrl":489,"body":71,"legacyUrl":71,"updatedAt":490,"createdAt":491,"_status":76},19,"COSBI and InSilicoTrials Announce Strategic Partnership to Revolutionize Drug Development and Regulatory Approval","cosbi-and-insilicotrials-announce-strategic-partnership-to-revolutionize-drug-de","2023-06-27T00:00:00.000Z","COSBI and InSilicoTrials launch a strategic partnership combining mechanistic modelling and AI-driven simulation to build a regulatory-grade computational infrastructure for drug development.","http:\u002F\u002Flocalhost:3001\u002Fapi\u002Fmedia\u002Ffile\u002FCosbi-_InSilico-press-release.pdf","2026-05-25T08:48:07.114Z","2026-05-25T07:59:58.627Z",{"id":493,"title":494,"slug":495,"date":496,"tag":69,"excerpt":497,"coverImage":71,"source":498,"externalUrl":499,"body":71,"legacyUrl":71,"updatedAt":500,"createdAt":501,"_status":76},20,"InSilicoTrials, IBSA Group Partner to Expand AI Use in Drug Development","insilicotrials-ibsa-group-partner-to-expand-ai-use-in-drug-development","2023-05-31T00:00:00.000Z","IBSA Group and InSilicoTrials announce a multi-year collaboration integrating AI-driven simulation into IBSA's preclinical and clinical development pipelines.","Press release · IBSA","http:\u002F\u002Flocalhost:3001\u002Fapi\u002Fmedia\u002Ffile\u002FPress_Release_collab_IBSA.pdf","2026-05-25T08:48:07.067Z","2026-05-25T07:59:58.650Z",{"id":503,"title":504,"slug":505,"date":506,"tag":69,"excerpt":507,"coverImage":71,"source":451,"externalUrl":508,"body":71,"legacyUrl":71,"updatedAt":509,"createdAt":510,"_status":76},21,"InSilicoTrials and AchilleS Vaccines Join Forces to Create Next-Generation Vaccines and Monoclonal Antibodies against Infectious Diseases","insilicotrials-and-achilles-vaccines-join-forces-to-create-next-generation-vacci","2023-04-27T00:00:00.000Z","InSilicoTrials and AchilleS Vaccines announce a collaboration combining computational vaccine design with advanced mAb modelling tools to tackle infectious diseases with limited therapeutic options.","http:\u002F\u002Flocalhost:3001\u002Fapi\u002Fmedia\u002Ffile\u002FPress_Release_collab_achiles.pdf","2026-05-25T08:48:07.001Z","2026-05-25T07:59:58.675Z",{"id":512,"title":513,"slug":514,"date":515,"tag":362,"excerpt":516,"coverImage":71,"source":517,"externalUrl":518,"body":71,"legacyUrl":71,"updatedAt":519,"createdAt":520,"_status":76},24,"Health Campus Welcomes InSilicoTrials and Delta Healthcare as New Companies in Limburg","health-campus-welcomes-insilicotrials-and-delta-healthcare-as-new-companies-in-l","2023-03-20T00:00:00.000Z","InSilicoTrials establishes its presence at the Health Campus in Limburg, Belgium, joining an innovation hub focused on advancing life sciences and digital health in the region.","Press release · POM Limburg","http:\u002F\u002Flocalhost:3001\u002Fapi\u002Fmedia\u002Ffile\u002FPress_Release_POM.pdf","2026-05-25T08:48:06.791Z","2026-05-25T08:44:58.937Z",{"id":522,"title":523,"slug":524,"date":525,"tag":69,"excerpt":526,"coverImage":71,"source":527,"externalUrl":528,"body":71,"legacyUrl":71,"updatedAt":529,"createdAt":530,"_status":76},22,"Premier Research and InSilicoTrials Partner to Leverage In Silico Modeling and Simulation and Optimize Regulatory Pathways for Rare Disease Therapies","premier-research-insilicotrials-partner-to-leverage-in-silico-modeling-and-simul","2023-03-13T00:00:00.000Z","Premier Research embeds InSilicoTrials' platform into its rare-disease CRO offering — providing sponsors with simulation-led regulatory strategy to reduce development timelines.","Press release · Premier Research","http:\u002F\u002Flocalhost:3001\u002Fapi\u002Fmedia\u002Ffile\u002FPremier-Research-and-InSilicoTrials-Partner-to-Leverage-In-Silico-Modeling-and-Simulation-and-Optimize-Regulatory-Pathways-for-Rare-Disease-Therapies48.pdf","2026-05-25T08:48:06.903Z","2026-05-25T07:59:58.709Z",{"id":532,"title":533,"slug":534,"date":535,"tag":290,"excerpt":536,"coverImage":71,"source":537,"externalUrl":538,"body":71,"legacyUrl":71,"updatedAt":539,"createdAt":540,"_status":76},23,"InSilicoTrials' Research Paper Published in the Special Issue 'Modeling for Advancing Regulatory Science' by Annals of Biomedical Engineering (ABME)","insilicotrials-research-paper-published-in-the-special-issue-modeling-for-advanc","2023-01-25T00:00:00.000Z","Peer-reviewed validation of the platform's simulation methodology — published in the ABME special issue dedicated to regulatory-science modeling.","Research · ABME","http:\u002F\u002Flocalhost:3001\u002Fapi\u002Fmedia\u002Ffile\u002FPress_Release_January23.pdf","2026-05-25T08:48:06.842Z","2026-05-25T07:59:58.746Z",{"id":542,"title":543,"slug":544,"date":545,"tag":69,"excerpt":546,"coverImage":71,"source":421,"externalUrl":547,"body":71,"legacyUrl":71,"updatedAt":548,"createdAt":549,"_status":76},25,"LSD and InSilicoTrials to Help Biotechs Speed Up Innovation","lsd-and-insilicotrials-to-help-biotechs-speed-up-innovation","2022-12-13T00:00:00.000Z","LSD and InSilicoTrials announce a partnership to accelerate digital transformation for biotech companies, combining laboratory and computational expertise to streamline drug development workflows.","http:\u002F\u002Flocalhost:3001\u002Fapi\u002Fmedia\u002Ffile\u002FPress_Release_collab_LSD.pdf","2026-05-25T08:48:06.733Z","2026-05-25T08:44:58.968Z",{"id":551,"title":552,"slug":553,"date":554,"tag":362,"excerpt":555,"coverImage":71,"source":421,"externalUrl":556,"body":71,"legacyUrl":71,"updatedAt":557,"createdAt":558,"_status":76},26,"InSilicoTrials CEO Luca Emili Joins QUAES-UPF Roundtable on Good Practices and Ethics in In Silico Medicine","insilicotrials-ceo-luca-emili-joins-quaes-upf-roundtable-on-good-practices-and-e","2022-06-30T00:00:00.000Z","InSilicoTrials CEO Luca Emili participates as a panelist at the QUAES-UPF Roundtable on Good Practices and Ethics in in silico Medicine, closing the 6th VPH Summer School.","http:\u002F\u002Flocalhost:3001\u002Fapi\u002Fmedia\u002Ffile\u002FPress_Release_June.pdf","2026-05-25T08:48:06.686Z","2026-05-25T08:44:59.001Z",{"id":560,"title":561,"slug":562,"date":563,"tag":69,"excerpt":564,"coverImage":71,"source":421,"externalUrl":565,"body":71,"legacyUrl":71,"updatedAt":566,"createdAt":567,"_status":76},27,"RCPE and InSilicoTrials to Digitalize and Accelerate the Development of Pharmaceutical Manufacturing Processes","rcpe-and-insilicotrials-to-digitalize-and-accelerate-the-development-of-pharmace","2022-05-30T00:00:00.000Z","RCPE and InSilicoTrials expand their collaboration to apply advanced simulation tools to pharmaceutical manufacturing process development, reducing time-to-market for solid dosage forms.","http:\u002F\u002Flocalhost:3001\u002Fapi\u002Fmedia\u002Ffile\u002FPress_Release_IST_RCPE.pdf","2026-05-25T08:48:06.645Z","2026-05-25T08:44:59.037Z",{"id":569,"title":570,"slug":571,"date":572,"tag":69,"excerpt":573,"coverImage":71,"source":421,"externalUrl":574,"body":71,"legacyUrl":71,"updatedAt":575,"createdAt":576,"_status":76},28,"Medacta and InSilicoTrials Partner to Take Medical Device Development to the Next Level","medacta-and-insilicotrials-partner-to-take-medical-device-development-to-the-nex","2022-04-20T00:00:00.000Z","Medacta and InSilicoTrials announce a partnership to apply computational simulation to orthopaedic medical device development, accelerating regulatory submissions and reducing animal testing.","http:\u002F\u002Flocalhost:3001\u002Fapi\u002Fmedia\u002Ffile\u002FIST_MEDACTA__PRESS-RELEASE.pdf","2026-05-25T08:48:06.604Z","2026-05-25T08:44:59.066Z",{"id":578,"title":579,"slug":580,"date":581,"tag":362,"excerpt":582,"coverImage":71,"source":421,"externalUrl":583,"body":71,"legacyUrl":71,"updatedAt":584,"createdAt":585,"_status":76},31,"RCPE and InSilicoTrials Add New Tool to Their XPS Simulation Software","rcpe-and-insilicotrials-add-new-tool-to-their-xps-simulation-software","2022-02-28T00:00:00.000Z","RCPE and InSilicoTrials expand the XPS simulation software suite with a new tablet coating simulation module, enabling pharmaceutical companies to digitally optimise manufacturing processes.","http:\u002F\u002Flocalhost:3001\u002Fapi\u002Fmedia\u002Ffile\u002FPR_RCPE_SimTabletCoater.pdf","2026-05-25T08:48:06.394Z","2026-05-25T08:44:59.236Z",{"id":587,"title":588,"slug":589,"date":590,"tag":69,"excerpt":591,"coverImage":71,"source":421,"externalUrl":592,"body":71,"legacyUrl":71,"updatedAt":593,"createdAt":593,"_status":76},29,"IonsGate Preclinical Services and InSilicoTrials Together to Innovate Drug Discovery","ionsgate-preclinical-services-and-insilicotrials-together-to-innovate-drug-disco","2022-02-02T00:00:00.000Z","IonsGate Preclinical Services and InSilicoTrials form a strategic partnership combining experimental ion channel expertise with computational modelling to accelerate early-stage drug discovery.","https:\u002F\u002Finsilicotrials.com\u002Fwp-content\u002Fuploads\u002F2022\u002F02\u002FPress_Release_IonsGate.pdf","2026-05-25T08:44:59.109Z",{"id":595,"title":596,"slug":597,"date":598,"tag":430,"excerpt":599,"coverImage":71,"source":600,"externalUrl":601,"body":71,"legacyUrl":71,"updatedAt":602,"createdAt":602,"_status":76},30,"Mario Torchia Joins InSilicoTrials as VP Sales & Marketing","mario-torchia-joins-insilicotrials-as-vp-sales-marketing","2022-01-18T00:00:00.000Z","Mario Torchia joins InSilicoTrials as Vice President of Sales & Marketing, bringing extensive commercial experience in life sciences technology to drive international growth.","News · BioSpectrum Asia","https:\u002F\u002Fwww.biospectrumasia.com\u002Fnews\u002F46\u002F19603\u002Fmario-torchia-joins-insilicotrials-as-vp-sales-marketing.html","2026-05-25T08:44:59.155Z",{"id":604,"title":605,"slug":606,"date":607,"tag":69,"excerpt":608,"coverImage":71,"source":609,"externalUrl":610,"body":71,"legacyUrl":71,"updatedAt":611,"createdAt":611,"_status":76},32,"DSTC and InSilicoTrials Partner Up to Innovate Drug Development","dstc-and-insilicotrials-partner-up-to-innovate-drug-development","2021-11-11T00:00:00.000Z","DSTC and InSilicoTrials announce a partnership to integrate advanced computational tools into drug development workflows, combining domain expertise to deliver faster and more predictive preclinical assessments.","News · PharmiWeb","https:\u002F\u002Fwww.pharmiweb.jobs\u002Farticle\u002Fdstc-and-insilicotrials-partner-up-to-innovate-drug-development-","2026-05-25T08:44:59.259Z",{"id":613,"title":614,"slug":615,"date":616,"tag":92,"excerpt":617,"coverImage":71,"source":618,"externalUrl":619,"body":71,"legacyUrl":71,"updatedAt":620,"createdAt":620,"_status":76},33,"Italy Outlines Pathways to the Adoption of In Silico Medicine to Innovate Healthcare","italy-outlines-pathways-to-the-adoption-of-in-silico-medicine-to-innovate-health","2021-10-28T00:00:00.000Z","A national Italian initiative outlines strategic pathways for integrating in silico medicine into healthcare innovation, establishing a framework for regulatory acceptance and clinical adoption.","News · Lab Worldwide","https:\u002F\u002Fwww.lab-worldwide.com\u002Fitaly-outlines-pathways-to-the-adoption-of-in-silico-medicine-to-innovate-healthcare-a-1070434\u002F","2026-05-25T08:44:59.281Z",{"id":622,"title":623,"slug":624,"date":625,"tag":362,"excerpt":626,"coverImage":71,"source":627,"externalUrl":628,"body":71,"legacyUrl":71,"updatedAt":629,"createdAt":630,"_status":76},34,"InSilicoTrials Releases Two New State-of-the-Art Simulation Tools for Oncology","insilicotrials-releases-two-new-state-of-the-art-simulation-tools-for-oncology","2021-10-19T00:00:00.000Z","InSilicoTrials launches two new oncology simulation modules, enabling pharmaceutical researchers to model tumour response and chemotherapy toxicity profiles in virtual patient populations.","News · PharmaMirror","https:\u002F\u002Fwww.pharmamirror.com\u002Fnews-center\u002Fworld-pharmaceutical-news\u002Finsilicotrials-releases-two-new-state-of-the-art-simulation-tools-for-oncology\u002F","2026-05-25T08:44:59.304Z","2026-05-25T08:44:59.303Z",{"id":632,"title":633,"slug":634,"date":635,"tag":69,"excerpt":636,"coverImage":71,"source":421,"externalUrl":637,"body":71,"legacyUrl":71,"updatedAt":638,"createdAt":638,"_status":76},35,"InSilicoTrials and Galileo Research Announce Partnership to Reduce Time and Cost of Drug Development","insilicotrials-and-galileo-research-announce-partnership-to-reduce-time-and-cost","2021-09-22T00:00:00.000Z","InSilicoTrials and Galileo Research announce a collaboration to apply computational simulation to drug development, aiming to reduce costs and timelines for early-phase clinical research.","https:\u002F\u002Fpharmafield.co.uk\u002Fpharma_news\u002Finsilico-trials-and-galileo-research-partner-to-reduce-time-and-cost-of-drug-development\u002F","2026-05-25T08:44:59.332Z",{"id":640,"title":641,"slug":642,"date":643,"tag":69,"excerpt":644,"coverImage":71,"source":645,"externalUrl":646,"body":71,"legacyUrl":71,"updatedAt":647,"createdAt":647,"_status":76},36,"Takeda, RCPE, InSilicoTrials and University of Graz Partner to Optimise Biopharmaceutical Manufacturing Processes","takeda-rcpe-insilicotrials-and-university-of-graz-partner-to-optimise-biopharmac","2021-06-21T00:00:00.000Z","Takeda, RCPE, InSilicoTrials and the University of Graz launch a multi-institutional collaboration to apply computational modelling to biopharmaceutical manufacturing, targeting fill-and-finish process optimisation.","Press release · RCPE","https:\u002F\u002Fwww.pressebox.de\u002Finaktiv\u002Fresearch-center-pharmaceutical-engineering-gmbh\u002FPartnerschaft-von-Takeda-RCPE-InSilicoTrials-und-der-Karl-Franzens-Universitaet-Graz-zur-Optimierung-biopharmazeutischer-Herstellungsprozesse\u002Fboxid\u002F1064610","2026-05-25T08:44:59.355Z",{"id":649,"title":650,"slug":651,"date":652,"tag":362,"excerpt":653,"coverImage":71,"source":654,"externalUrl":655,"body":656,"legacyUrl":71,"updatedAt":763,"createdAt":764,"_status":76},37,"How to accelerate the uptake of simulation in healthcare","insilicotrials-wins-3-eu-horizon-2020-projects-to-accelerate-innovation-in-healt","2021-04-16T00:00:00.000Z","InSilicoTrials is selected as partner in three EU Horizon 2020 projects — BRAINTEASER, SimCardioTest, and In Silico World — cementing its position as a key player in European computational medicine.","News · WorldPharmaToday","https:\u002F\u002Fwww.worldpharmatoday.com\u002Fnews\u002Finsilicotrials-wins-3-horizon-2020-projects-to-support-innovation\u002F",{"root":657},{"type":98,"format":9,"indent":99,"version":4,"children":658},[659,702,714,726,753,757],{"type":102,"format":9,"indent":99,"version":4,"children":660},[661,668,670,676,678,684,686,692,694,700],{"url":662,"type":113,"fields":663,"version":4,"children":665},"https:\u002F\u002Finsilico.world\u002F",{"url":662,"newTab":664,"linkType":116},false,[666],{"text":667,"type":106,"format":99,"version":4},"In Silico",{"text":669,"type":106,"format":99,"version":4}," World is one of the three",{"url":671,"type":113,"fields":672,"version":4,"children":673},"https:\u002F\u002Fec.europa.eu\u002Fprogrammes\u002Fhorizon2020\u002F",{"url":671,"newTab":664,"linkType":116},[674],{"text":675,"type":106,"format":99,"version":4}," ",{"text":677,"type":106,"format":99,"version":4},"Horizon 2020 funded projects ",{"url":679,"type":113,"fields":680,"version":4,"children":681},"https:\u002F\u002Fumx.369.myftpupload.com\u002F",{"url":679,"newTab":664,"linkType":116},[682],{"text":683,"type":106,"format":99,"version":4},"InSilicoTrials Technologies",{"text":685,"type":106,"format":99,"version":4}," is part of. We are in a consortium of 17 international partners, coordinated by the ",{"url":687,"type":113,"fields":688,"version":4,"children":689},"https:\u002F\u002Fwww.unibo.it\u002Fen",{"url":687,"newTab":664,"linkType":116},[690],{"text":691,"type":106,"format":99,"version":4},"University of Bologna",{"text":693,"type":106,"format":99,"version":4},", that will receive €7.6 million funds by the ",{"url":695,"type":113,"fields":696,"version":4,"children":697},"https:\u002F\u002Fec.europa.eu\u002F",{"url":695,"newTab":664,"linkType":116},[698],{"text":699,"type":106,"format":99,"version":4},"European Commission",{"text":701,"type":106,"format":99,"version":4}," to develop 11 in silico trials solutions leveraging state-of-the-art computational technologies to test the safety and\u002For the efficacy of medical devices, medicinal products, and even advanced therapy medicinal products such as tissue engineering constructs for regenerative medicine. ",{"type":102,"format":9,"indent":99,"version":4,"children":703},[704,706,712],{"text":705,"type":106,"format":99,"version":4},"The solutions will focus on some serious diseases such as osteoporosis, tuberculosis, multiple sclerosis, coronary stenosis, cerebral aneurysms, mammary carcinoma, and Covid-19 infection. As these advanced models are further improved, the consortium will also work on the definition and development of: data collections for validation; technical standards and regulatory pathways for qualification; policy documents and information packages for citizens, patients, clinicians, senior management in medical industries; computational strategies to improve scalability and efficiency of simulations; new curricula to educate the workforce on the development and use of ",{"url":707,"type":113,"fields":708,"version":4,"children":709},"https:\u002F\u002Fumx.369.myftpupload.com\u002Ftechnology\u002F",{"url":707,"newTab":664,"linkType":116},[710],{"text":711,"type":106,"format":78,"version":4},"in silico trials",{"text":713,"type":106,"format":99,"version":4}," technologies; and robust business models for the commercial exploitation of these innovative solutions. All with focused attention to legal and ethical implications of such disruptive technologies.",{"type":102,"format":9,"indent":99,"version":4,"children":715},[716,718,724],{"text":717,"type":106,"format":99,"version":4},"The 17 members of the consortium - coming from 6 different European countries (Italy, Belgium, The Netherlands, Germany, Poland, and Hungary) - include 7 universities (Alma Mater Studiorum – University of Bologna; Universiteit van Amsterdam; Eindhoven University of Technology; Università degli Studi di Catania; Katholieke Universiteit Leuven; University of Liège; Budapest University of Technology and Economics), 3 companies (InSilicoTrials; Mimesis; RSscan International), 4 research hospitals (Istituto Ortopedico Rizzoli, Bologna; Garibaldi Hospital, Catania; National Institute of Clinical Neurosciences, Budapest; Erasmus Medical Centre), 1 International research centre (Sano Foundation), 1 non-governmental organisation (",{"url":719,"type":113,"fields":720,"version":4,"children":721},"https:\u002F\u002Fwww.vph-institute.org\u002F",{"url":719,"newTab":664,"linkType":116},[722],{"text":723,"type":106,"format":99,"version":4},"VPH Institute",{"text":725,"type":106,"format":99,"version":4},"), and 1 standardisation body (DIN, Deutsches Institut für Normung).",{"type":102,"format":9,"indent":99,"version":4,"children":727},[728,730,735,737,743,745,751],{"text":729,"type":106,"format":99,"version":4},"Our tech company - founded in 2018 by a team of life sciences, cybersecurity, and digital innovation experts - aims to democratize the use of modeling and simulations in healthcare through a unique cloud simulation platform that is easy to use and cost-effective. Within In Silico World, we will lead the analysis of the business opportunities for the technological solutions developed during the project, aiming to maximize the impact and the commercial exploitation of the tools through the marketplace platform ",{"url":679,"type":113,"fields":731,"version":4,"children":732},{"url":679,"newTab":664,"linkType":116},[733],{"text":734,"type":106,"format":99,"version":4},"InSilicoTrials.com",{"text":736,"type":106,"format":99,"version":4},". Our CEO and Founder ",{"url":738,"type":113,"fields":739,"version":4,"children":740},"https:\u002F\u002Fwww.linkedin.com\u002Fin\u002Fluca-emili\u002F",{"url":738,"newTab":664,"linkType":116},[741],{"text":742,"type":106,"format":99,"version":4},"Luca Emili",{"text":744,"type":106,"format":99,"version":4},", who is also Leader of the Good Simulation Practice Task Force at the ",{"url":746,"type":113,"fields":747,"version":4,"children":748},"https:\u002F\u002Favicenna-alliance.com\u002F",{"url":746,"newTab":664,"linkType":116},[749],{"text":750,"type":106,"format":99,"version":4},"Avicenna Alliance",{"text":752,"type":106,"format":99,"version":4},", will have the role of Innovation Manager, monitoring the project results’ exploitation and helping partners to develop intellectual property rights strategy.",{"type":102,"format":9,"indent":99,"version":4,"children":754},[755],{"text":756,"type":106,"format":99,"version":4},"The ambitious goal of this 4-year project is to lower barriers to adoption and accelerate the uptake of simulation in healthcare and the development and regulatory assessment of medicines and medical devices. The long-term impact of this cutting-edge technology will be the drastic reduction of animal testing, human testing, and development costs and duration, while maintaining or improving the level of safety provided by traditional approaches. This means lower price and shorter time-to-market for new medical products and devices, eventually resulting in better treatments and cures for a higher number of patients. ",{"type":102,"format":9,"indent":99,"version":4,"children":758},[759],{"url":662,"type":113,"fields":760,"version":4,"children":761},{"url":662,"newTab":664,"linkType":116},[762],{"text":662,"type":106,"format":99,"version":4},"2026-05-25T09:02:15.148Z","2026-05-25T08:44:59.379Z",50,{"id":4,"siteTitle":767,"siteDescription":768,"defaultOgImage":71,"footerCopy":769,"featuredContent":770,"updatedAt":779,"createdAt":780,"globalType":781},"InSilicoTrials","The simulation layer for drug development.","2017–2026 © InSilicoTrials Technologies. All rights reserved. · Made with ❤️ by the IST Dev Team",[771,774,777],{"id":772,"contentType":773,"article":71,"newsItem":4,"researchProject":71,"overrideImage":71},"6a2bd2c713e9177f31f09ae8","news",{"id":775,"contentType":776,"article":71,"newsItem":71,"researchProject":297,"overrideImage":71},"6a2bd2d113e9177f31f09aea","research-projects",{"id":778,"contentType":773,"article":71,"newsItem":78,"researchProject":71,"overrideImage":71},"6a2bd57e13e9177f31f09aec","2026-06-19T08:57:09.309Z","2026-06-12T09:35:23.693Z","settings"]